Asthma Treatment Market - Databook 2025 to 2034

The global asthma treatment market size was evaluated at USD 28,300 million in 2024 and is expected to grow around USD 36,230 million by 2034, registering a CAGR of 2.5% from 2025 to 2034.

Highlights of the Asthma Treatment Market

• North America dominated the global asthma treatment market in 2024.
• Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period.
• By treatment, the long-term control medications segment will hold a dominant presence in the market in 2024.
• By treatment, the quick-relief medications segment is expected to grow at the fastest rate in the asthma treatment market during the forecast period.
• By route of administration, the inhaled segment holds a dominant presence in the market in 2024.
• By route of administration, the injectable segment is expected to grow at the fastest rate in the asthma treatment market during the forecast period.
• By route of administration, the oral segment shows a notable growth in the market during the forecast period.
• By distribution channel, the hospital pharmacies segment holds a dominant presence in the asthma treatment market in 2024.
• By distribution channel, the retail pharmacies & drug stores segment is expected to grow at the fastest rate in the market during the forecast period.
• By distribution channel, the online pharmacies segment shows a notable growth in the market during the forecast period.

Industry Valuation and Growth Rate Projection

Asthma is a state by which the airways narrow and swell, ending up with extra mucus formation. It is a minor annoyance for a few people. For many, it can be a major problem that disturbs daily activities and can end up in a life-threatening asthma attack, which is also known as asthma exacerbation. The rising prevalence of asthma, increasing information about asthma medications, and developments in asthma treatment alternatives are projected to impetus market expansion. Industry is thus driven by environmental factors like air pollution, lifestyle changes, and allergens, which lead to the surged incidence of asthma globally.

Asthma Treatment Market: Stats and Figures

• Asthma is a chronic non-communicable disorder that affects nearly 260 million individuals and is the reason for over 450000 deaths every year globally, most of which are preventable.
• In January 2025, Novo Holdings reported that it had funded a $200M Series A launch financing for Windward Bio, a clinical-platform drug development firm committed to
• enhancing results for people living with the latest immunological disorders with an initial target on severe respiratory conditions.

How AI Has Benefitted the Asthma Treatment Market

• Artificial intelligence (AI) algorithms are anticipated to change the future of healthcare in medical imaging determination, remote patient care, drug discovery, rehabilitation, and diagnostics.
• AI, mainly machine learning, has been broadly considered as transformative when registered to asthma care. This commentary explores how AI and ML may enhance clinical results while alleviating a few of the expenses linked with asthma care.
• AI's effective analytical capabilities could guide in an unprecedented era of preventive measures, mainly by determining at-risk populations and expecting environmental triggers. ML showcases its promise for improving early detection, real-time monitoring, and tailored treatment methods in paediatric asthma, potentially decreasing emergency care and hospitalization expenses.
• Emerging AI-derived wearable technologies are catalyzing a transformative shift in patient monitoring, offering proactive interventions. Thus, optimistic, this commentary spotlights a gap in empirical studies determining the expense-effectiveness of AI in stresses and asthma care and the demand for larger datasets to represent the economic advantageous of AI solutions.

Industry Leader Announcements

• Eric Hughes, MD, PhD, Executive Vice President, Teva Global R&D and Chief Medical Officer

“As we execute our Pivot to Growth Strategy, we are focused on accelerating our late-stage innovative pipeline and delivering meaningful new therapies to people living with unmet medical need,” said Eric Hughes, MD, PhD, Executive Vice President, Teva Global R&D and Chief Medical Officer. “We are especially excited about the potential to deliver this new asthma therapy to patients working alongside the team at Launch Therapeutics, who have valuable experience in expediting clinical development programs.”

• George D. Yancopoulos, M.D., Ph.D., Board Co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent

“This latest FDA approval for Dupixent represents new hope for the hundreds of thousands of COPD patients in the U.S. who can sometimes struggle just to breathe during their everyday lives,” said George D. Yancopoulos, M.D., Ph.D., Board Co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. “Dupixent has a proven track record as a first-in-class medicine, providing benefit to the many patients suffering from type 2 inflammatory related diseases such as asthma and atopic dermatitis. This latest approval represents an important next chapter for Dupixent, giving those with COPD a novel option that has demonstrated the unprecedented ability to help patients experience fewer exacerbations, while also helping them breathe better and improve quality of life in Phase 3 trials.”

Geographical Insights

The asthma treatment market is experiencing significant growth, with North America maintaining its position as the dominant region while Europe emerges as the rapidly growing market. In the APAC region, China stands out as a driver of growth in the space.

North America

North America dominated the global market in 2024. This is due to the robust existence of key players, well-known infrastructure, a growing incidence of diseases, increasing air pollution, growing geriatric population, and increasing need for high-efficiency and fast-acting efficacy drugs are some other factors boosting market expansion.

Europe

Europe is experiencing rapid growth in the asthma treatment market during the forecast period. Asthma, with its elevated global incidence and the need for novel treatments and diagnostics, presents a huge opportunity to boost substantial economic expansion. Europe may also have capitalized on this through funding in research with huge commercial potential that can radically enhance European research and public health.

China and APAC

Asia Pacific (APAC) is projected to be the fastest growing in the market during the forecast period. Reimbursement policies and government initiatives to enhance treatment quality, encourage evidence-derived practices, and decrease healthcare inconsistencies are promoting asthma therapy acceptance in China, targeting research & development to create new treatments, enhance drug delivery systems, and determine asthma pathophysiology extend to broader consumers.

Recent Developments

• In April 2024, Launch Therapeutics, Inc. and Teva Pharmaceutical Industries Ltd. disclosed a clinical working agreement to thus speed up the clinical research scheme of Teva’s ICS-SABA.

Competitive Landscape

The competitive landscape in the asthma treatment market is greatly competitive and dynamic, with numerous multinational pharmaceutical firms and an increasing number of biotechnology companies vying for market share. For example, AstraZeneca has successfully initiated products focusing on severe asthma, significantly with biologics like tezepelumab in late-phase clinical evolution.

• Company Name: GSK plc
• Year of Incorporation: 2000
• Headquarters: London, United Kingdom

GSK plc is a healthcare firm that targets developing, producing, and commercializing general medicines, vaccines, and specialty medicines. It provides drugs for the therapy of disorders such as HIV, cancer, respiratory, immuno-inflammation, central nervous system (CNS), anti-viral, dermatology, metabolic, urogenital, cardiovascular, anti-bacterial, and rare diseases. The firm also provides over-the-counter (OTC) items for pain relief, nutrition, oral health, skin health, and gastrointestinal disorders.

• Company Name: AstraZeneca
• Year of Incorporation: 1999
• Headquarters: Cambridge, United Kingdom

AstraZeneca is considered one of the major pharmaceutical firms in the world. It tackles opportunities and challenges in the greatly competitive healthcare domain. From growing lifesaving drugs to strengthening the latest research, it continues to make a remarkable impact on health. With a strong target on boosting growth and conveying value to its stakeholders, it is highly placed to direct the complex diligent environment and manage its position as a major player in the pharmaceutical domain.

• Company Name: Novartis AG
• Year of Incorporation: 1996
• Headquarters: Basel, Switzerland

Novartis AG is a healthcare firm that targets the discovery, production, development, and marketing of generic and prescription pharmaceutical items and eye care products. It offers drugs for the therapy of cancer, dermatological conditions, cardiovascular diseases, neurological disorders, hematologic diseases, immune disorders and infections, ophthalmic and respiratory diseases, and solid tumors, among others. These perform research in numerous disease areas via the BioMedical Research division.